Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
-
1701
-
1702
Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for Brazil.
Published 2016Subjects: -
1703
Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Caribbean.
Published 2016Subjects: -
1704
Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Southern Cone.
Published 2016Subjects: -
1705
Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Andean region.
Published 2016Subjects: -
1706
Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the Mesoamerican region.
Published 2016Subjects: -
1707
Drug resistance mutation frequency comparison, 2000–2005 vs. 2006–2015, for the whole LAC region.
Published 2016Subjects: -
1708
-
1709
-
1710
-
1711
-
1712
-
1713
-
1714
-
1715
-
1716
-
1717
-
1718
-
1719
Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner.
Published 2013“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”
-
1720
List of Included studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”